文献速递神经免疫

疾病修正治疗与复发型多发性硬化伴孤立MRI活动患者结局的关联

Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
PubMed 文献 · Neurology · 2024-08-28

该多中心队列研究纳入131例临床稳定的复发型多发性硬化患者,评估基于孤立MRI活动升级疾病修正治疗对临床结局的影响。中位随访6年,47%患者复发;2个新T2病灶时继续一线治疗复发风险增加3倍(HR 3.2),≥3个时增加4倍(HR 4.0);升级治疗使2个新T2病灶者复发风险降低约80%(HR 0.2),≥3个者降低70%(HR 0.3);仅1个新T2病灶时风险增加和治疗效应均未达5%统计学显著。

要点

  • 临床稳定患者出现≥2个新T2病灶时,继续低中效治疗复发风险增加3-4倍。
  • 基于孤立MRI活动升级治疗可降低后续复发风险约70-80%。
  • 仅1个新T2病灶时,复发风险增加与治疗效应均未达统计学显著。

核心结论

  • 在临床稳定的低中效疾病修正治疗患者中,基于孤立MRI活动升级治疗在出现至少2个新T2病灶时降低进一步复发风险。

研究设计与样本

  • 结合奥地利和瑞士5个多发性硬化中心数据的队列研究,纳入131例年龄至少18岁的复发型多发性硬化患者。
  • 纳入条件:启动一线低中效疾病修正治疗(干扰素β、醋酸格拉替雷、特立氟胺或富马酸二甲酯)并持续≥12个月;治疗12个月内临床稳定(无复发或残疾进展);基线和治疗12个月时有MRI;第二次MRI后有≥2年临床随访。
  • 主要终点为随访期间复发发生;回归分析协变量为新T2病灶数和治疗策略(继续低中效治疗 vs 升级治疗)。

主要发现

  • 131例患者中位年龄36岁(25-75百分位数29-43),73%为女性,第二次MRI后中位观察6年(5-9年)。
  • 62例(47%)患者发生复发。
  • 继续一线治疗者,2个新T2病灶时复发风险增加3倍(HR 3.2,95%CI下限1.5),≥3个新T2病灶时增加4倍(HR 4.0,95%CI下限2.1)。
  • 升级治疗使2个新T2病灶者复发风险降低约80%(HR 0.2,95%CI上限1.3),≥3个新T2病灶者降低70%(HR 0.3,95%CI上限0.8)。
  • 仅1个新T2病灶时,复发风险增加和治疗效应均未达5%统计学显著。

关键数值与推荐

  • 该研究提供III级证据:临床稳定的多发性硬化患者接受低中效疾病修正治疗时,若MRI显示≥3个新T2病灶,升级治疗可降低复发风险和扩展残疾状态量表进展风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Isolated value of MRI metrics in relapsing multiple sclerosis (RMS) as a surrogate marker of response to disease-modifying treatment (DMT) and, thus, as decision criteria for DMT escalation in the absence of clinical signs of disease activity is still a matter of debate. The aim of this study was to investigate whether DMT escalation based on isolated MRI activity affects clinical outcome. METHODS: Combining data from 5 MS centers in Austria and Switzerland, we included patients with RMS aged at least 18 years who (1) had initiated first-line, low-to-moderate-efficacy DMT (interferon β, glatiramer acetate, teriflunomide, or dimethyl fumarate) continued for ≥12 months, (2) were clinically stable (no relapses or disability progression) on DMT for 12 months, (3) had MRI at baseline and after 12 months on DMT, and (4) had available clinical follow-up for ≥2 years after the second MRI. The primary endpoint was occurrence of relapse during follow-up. The number of new T2 lesions (T2L) and DMT strategy (continuing low-/moderate-efficacy DMT vs escalating DMT) were used as covariates in regression analyses. RESULTS: A total of 131 patients with RMS, median age of 36 (25th-75th percentiles: 29-43) years, 73% women, were included and observed over a median period of 6 (5-9) years after second MRI. Sixty-two (47%) patients had relapse. Patients who continued first-line DMT had a 3-fold increased risk of relapse given 2 new T2L (hazard ratio [HR] 3.2, lower limit [LL] of 95% CI: 1.5) and a 4-fold increased risk given ≥3 new T2L (HR 4.0, LL-CI: 2.1). Escalation of DMT lowered the risk of relapse in patients with 2 new T2L by approximately 80% (HR 0.2, upper limit [UL] of 95% CI: 1.3) and with ≥3 new T2L by 70% (HR 0.3, UL-CI: 0.8). In case of only 1 new T2L, the increased risk of relapse and the treatment effect did not reach statistical significance of 5%. DISCUSSION: In our real-world cohort of patients clinically stable under low-to-moderate-efficacy DMT, escalation of DMT based on isolated MRI activity decreased risk of further relapse when at least 2 new T2L had occurred. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that clinically stable patients with MS on low-/moderate-efficacy DMT with ≥3 new T2L on MRI who escalate DMT have a reduced risk of relapse and Expanded Disability Status Scale progression.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bsteh G, Aicher ML, Walde JF, et al. Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity. Neurology. 2024. PMID: 39197111. doi:10.1212/WNL.0000000000209752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。